Latest News
Kinetic Sand Donated for Care Packages
We are incredibly grateful to have received a large shipment of Kinetic Sand Activity Kits to be included in the Newly Diagnosed Type II Care Packages in honor of Jayce’s […]
Read More ›Isis Expands Phase 3 Clinical Trials
Isis recently announced that they have tested the first patient in CHERISH, a multi-center Phase 3 clinical study evaluating the efficacy and safety of the investigational compound, ISIS-SMNRx, in non-ambulatory […]
Read More ›SMA Drug Pipeline Continues to Grow
This is an exciting time for the entire SMA community, as we celebrate another year of increasing momentum toward our goal of a treatment and cure for SMA. It’s also […]
Read More ›Cure SMA Researchers Present at Society for Neuroscience Meeting
The Society for Neuroscience (SfN) Meeting is the premiere neurobiology meeting, with over 30,000 scientists in attendance each year. This year’s meeting was held November 15-19 in Washington D.C. Two […]
Read More ›PTC Therapeutics Announces New Phase 1a/2b Clinical Trial
PTC Therapeutics, Inc. announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a Phase 1b/2a study in adult […]
Read More ›Isis Announces Second Phase III Clinical Trial
Isis recently announced the start of CHERISH, a multi-center Phase III clinical study evaluating the efficacy and safety of the investigational compound, ISIS-SMNRx, in non-ambulatory children with Spinal Muscular Atrophy […]
Read More ›